# Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer

> **NCT06480864** · NA · RECRUITING · sponsor: **Yunpeng Liu** · enrollment: 38 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Adebrelimab Injection
- **DRUG:** Apatinib Mesylate Tablets
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT06480864
- **Lead sponsor:** Yunpeng Liu
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-09
- **Primary completion:** 2025-08
- **Final completion:** 2026-08
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06480864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06480864, "Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06480864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*